Industry Wire 238

January 10, 2025 Viktor Zarev 0 min read
  1. Investors call on UnitedHealth to disclose costs of policies that limit care.
  2. EHR costs at the 25 largest health systems.
  3. Cedars-Sinai becomes latest system to appoint a Chief Data and AI Officer.
  4. Healthcare Awareness Calendar: key dates for 2025.
  5. Blue Shield of California restructures, names Lois Quam as new CEO. 
  6. 11 systems back in the black, including Trinity and Cleveland Clinic.
  7. Virginia hospital indicted for performing unnecessary surgical procedures.
  8. Hospitals and California wildfires, what to know.
  9. Mark Cuban’s drug company nets MultiCare $1M in six months.
  10. Oldest woman in the world dies in Japan at age 116.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology November 13, 2025

The Best of AHA 2025 November 13, 2025

Cardiology conference season is coming to a close, and what better way to end the year than with the AHA 2025 Scientific Sessions meeting in New Orleans, Louisiana. From major pharma studies to smaller companies solving big problems and every cardiac subspeciality in between, here are Cardiac Wire’s top takeaways from AHA 2025. AHA 2025 […]

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]